Participating Companies

Participants in the pilot programme 2024

Here are descriptions of the companies that are taking part in the 10xHealth programme of 2024

Hanna Sjöström

CEO, Neola Medical

Neola Medical AB (publ) develops medical devices for continuous monitoring of the lungs of preterm born babies. Immediate detection of complications allows for early treatment and improved care. The patented technology is based on a spectroscopic method developed at Lund University in Sweden.

The company was founded in 2016 and is listed on NASDAQ First North Growth Market (ticker: NEOLA).

The company’s Certified Adviser is FNCA Sweden AB.

Linda Persson

CEO, NanoEcho

NanoEcho is a venture capital-funded medical technology company that originated from a research group at Lund University. The company is developing a product intended for diagnostics of rectal cancer by mapping the spread of cancer cells to nearby lymph nodes.

Currently, there is a lack of an effective method to detect the spread of cancer to nearby lymph nodes—a crucial piece of information for determining how far the cancer has advanced and determining the appropriate treatment for the patient.

Johan Wäborg

CEO, Iconovo

Iconovo is a Swedish leading CDMO company, offering innovative and effective inhalation platforms to the international pharmaceutical industry. We have several types of patented inhalers that can create significant commercial opportunities for the development of both new pharmaceuticals and generic medicine.

We are a well-established company with patent families and an extensive product pipeline. Our strategy is focused on three core areas: CDMO business, License agreements, and inhaler/product sales.

Cecilia Belfrage

CEO, Uman Sense

Uman Sense, a MedTech innovation company spun off from Lund University, is dedicated to enhancing people’s lives through modern mobile solutions to medical challenges. Their focus lies in creating innovative solutions at the convergence of medicine, mathematics, and mobile technology, with the ultimate goal of revolutionizing healthcare delivery for the benefit of patients.

Through groundbreaking research and development, Uman Sense has devised a mobile stroke alarm system that utilizes wearable technology and advanced algorithms to detect stroke symptoms early, potentially saving countless lives by enabling timely intervention and treatment.

Erik Frick

CEO, Paindrainer

Paindrainer AB is a company developing digital platforms and applications contributing to health and well-being. Paindrainer® is the first evidence-based AI powered digital tool demonstrating improved quality of life in individuals living with chronic pain. The solution is powered by leveraging advanced algorithms and is fully adaptive to each user, a feature called 360o patient-centricity©.

Paindrainer® PD1 is an FDA registered Medical Device Class 1 (510k exemption), MDR compliant and CE certified. The company was founded in 2018 by Prof. Carl Borrebaeck, Dr. Maria Rosén Klement, and Göran Barkfors.

Carl-Magnus Högerkorp

CEO, Cyxone

Cyxone AB is a clinical stage biotech company specializing in the development of transformative therapies against autoimmune and autoinflammatory diseases. Our pipeline includes rabeximod, currently in Phase 2 clinical development for the treatment of rheumatoid arthritis and T20K, currently in early clinical development for the treatment of multiple sclerosis.